Related Experiment Video
Updated: Jan 14, 2026
A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
Published on: November 7, 2025
STEAP1-targeted strategies in advanced prostate cancer: a review on therapeutic and diagnostic implications
Ja Yoon Heo1,2, Minzhi Sheng3,4, Daniel Khalaf1,2
1Division of Medical Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.
Background/Objectives:
Six transmembrane epithelial antigen of prostate 1 (STEAP1), a cell surface protein, is highly expressed in prostate cancer and is known to be associated with disease progression and poor prognosis. Based on its specificity for prostate cancer, significant progress has been made over the past decade to capitalize on STEAP1 as a diagnostic and treatment target, and its potential future role in prostate cancer care is of considerable interest.
Subjects/Methods:
This review evaluates the current and emerging strategies targeting STEAP1, integrating findings from preclinical studies and clinical trials.
Results:
This review discusses STEAP1-based diagnostics, including molecular imaging (89Zr-DFO-MSTP2109A) and liquid biopsy methods, as well as therapeutics, such as STEAP1 antibodies, antibody-drug conjugates (DSPT3086S, ADRX-0405, ABBV-969, and DXC008), chimeric antigen receptor T-cell therapy (STEAP1 CAR-T), bispecific T-cell engagers (Xaluritamig/AMG 509, BC261), and cancer vaccines.
Conclusions:
STEAP1 represents a promising diagnostic and therapeutic target in prostate cancer, and its potential role in shaping future management of the disease warrants continued investigation.
More Related Videos
06:54MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
Published on: September 3, 2013
07:25A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
